Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Generated: April 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020908

« Back to Dashboard

NDA 020908 describes VAGIFEM, which is a drug marketed by Novo Nordisk Inc and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the VAGIFEM profile page.

The generic ingredient in VAGIFEM is estradiol. There are seventy-five drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the estradiol profile page.

Summary for 020908

Tradename:	VAGIFEM
Applicant:	Novo Nordisk Inc
Ingredient:	estradiol
Patents:	1
Therapeutic Class:	Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers)
Formulation / Manufacturing:	see details

Pharmacology for NDA: 020908

Ingredient-type	Estradiol Congeners
Mechanism of Action	Estrogen Receptor Agonists

Medical Subject Heading (MeSH) Categories for 020908

Estrogens

Suppliers and Packaging for NDA: 020908

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
VAGIFEM	estradiol	TABLET;VAGINAL	020908	NDA	Novo Nordisk	0169-5176	N	0169-5176-03
VAGIFEM	estradiol	TABLET;VAGINAL	020908	NDA	Novo Nordisk	0169-5176	N	0169-5176-99

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET;VAGINAL			Strength	25MCG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons
Approval Date:	Mar 26, 1999	TE:		RLD:	Yes

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;VAGINAL			Strength	10MCG
Approval Date:	Nov 25, 2009	TE:	AB	RLD:	Yes
Patent:	➤ Sign Up	Patent Expiration:	Sep 17, 2022	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE

Expired US Patents for NDA 020908

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novo Nordisk Inc	VAGIFEM	estradiol	TABLET;VAGINAL	020908-002	Nov 25, 2009	➤ Sign Up	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.